# CRISPR Therapeutics AG share price today (CRISPR Therapeutics AG, CRSP)

> CRISPR Therapeutics AG's share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. CRSP · Healthcare · Biotechnology · data as of 4 November 2026. Page: https://www.sectoralpha.in/us/stocks/crsp

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Price: $51.77 (−6.1% in a year)
- Revenue (Jun 2026): ₹0.0 B
- Profit (Jun 2026), incl. one-off: −₹0.1 B (one-off item, see below)
- ROE: −30%, FY25

Biggest thing to watch: the price is not yet in a clear uptrend, so timing is the risk more than the business. ## What is the CRISPR Therapeutics AG share price today? CRISPR Therapeutics AG's share price was $51.77 at the close on 4 November 2026. It has been falling for 4 weeks. That is 2.0% below its average price over the last 200 trading days. In the last 52 weeks it traded between $46 and $60, and at that close it sat 42% of the way up from that low. Over the past 13 weeks it has done worse than the S&P 500, and it has been behind for 1 week running. Over the last 10 years the share price moved +275% while the S&P 500 moved +258%, so it is ahead of the index over that whole period. It was last ahead over 13 weeks in the week of 30 October 2026. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What dividend does CRISPR Therapeutics AG pay? CRISPR Therapeutics AG pays no dividend. In the last 12 reported quarters it declared no dividend per share, so there is no payout history to chart and no yield to show. Companies like this usually keep their earnings in the business, so the cash-flow sections show where that cash goes. ## Which stock lists is CRISPR Therapeutics AG on? CRISPR Therapeutics AG is not in the Nasdaq 100, the S&P 500 or the Dow Jones 30, and is not on the US tech stocks list. ## Is CRISPR Therapeutics AG profitable? CRISPR Therapeutics AG posted a net loss of ₹0.1 B in the Jun 2026 quarter. That quarter includes a one-off gain bigger than its revenue, so the comparison with last year does not reflect normal business. The full FY25 year was a loss of ₹0.6 B. That loss is 895.3% of the quarter's revenue. The same quarter a year earlier lost ₹0.2 B. 11 of the last 12 reported quarters were loss-making. Read this profit with care: at −₹0.1 B it is bigger than the quarter's whole revenue of ₹0.0 B. No business earns more than it takes in from sales, so this is a one-off item (for example a debt settlement, a tax write-back or an asset sale), not money the business earned. The underlying business is running at a −1,127.6% operating margin. The jump on last year, and any P/E built on this profit, come from the one-off, not from a real turn in earnings. This company reports in its home currency, not US dollars, so the money charts are left out here. The figures in the text are in that currency (₹); nothing is converted. ## How much revenue does CRISPR Therapeutics AG make, and is it growing? CRISPR Therapeutics AG reported ₹0.0 B of revenue in the Jun 2026 quarter, +1,041.4% on the same quarter a year earlier. That is the 2nd quarter in a row with growth on the year before. Over 4 years it has grown −75.1% a year on average. The last full year, FY25, came in at ₹0.0 B. The last four reported quarters add to ₹0.0 B. FY25 revenue was ₹0.0 B, −90.6% on the year before. Recent pace: the last four quarters grew +265.0% on average, against −75.1% a year over the longer run, so this year is growing faster than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew −64.8%, against −77.8% a year over the last 8 quarters (accelerating). This company reports in its home currency, not US dollars, so the money charts are left out here. The figures in the text are in that currency (₹); nothing is converted. ## How much of its sales does CRISPR Therapeutics AG keep? CRISPR Therapeutics AG's sales have fallen to very little: FY25 revenue was ₹0.0 B, against ₹0.9 B in FY21. On sales that small an operating margin is not a useful reading, so this section is left out until sales recover. ## Is CRISPR Therapeutics AG's profit turning into cash? CRISPR Therapeutics AG's cash-flow history is too short to judge how much of its profit turns into cash. In FY25 its operations used ₹0.3 B of cash, against −₹0.6 B of profit. After ₹0.0 B of spending on assets, free cash was −₹0.3 B: it spent more than its operations brought in. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. What to look at next: it spends almost nothing on new assets, so the cash goes on running the business. The next section shows the spending figures. This company reports in its home currency, not US dollars, so the money charts are left out here. The figures in the text are in that currency (₹); nothing is converted. ## Where does CRISPR Therapeutics AG's cash go? CRISPR Therapeutics AG does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent ₹0.0 B on assets over the last 3 years. Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn. Spending on assets: ₹0.0 B over the last 3 years. In short: almost nothing is being spent on new assets, so the cash goes on running the business. This company reports in its home currency, not US dollars, so the money charts are left out here. The figures in the text are in that currency (₹); nothing is converted. ## What is CRISPR Therapeutics AG's P/E ratio, and how does it compare with its own history? CRISPR Therapeutics AG has no P/E right now, because its earnings are negative. The revenue and margin sections are where a turn would show first. The P/E comes back here once profit turns positive. ## Is the CRISPR Therapeutics AG business getting better or worse? CRISPR Therapeutics AG's business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend. This is based on 12 quarters of 2 measures, with some gaps. Why it matters: with too little history, we say so rather than guess a direction. The latest quarter’s profit includes a one-off item bigger than the normal business, so the profit line is shown but does not count in this reading. One or more growth lines have an extreme jump caused by comparing with a near-zero or loss-making quarter. Those jumps are capped before reading and drawn at the edge of the chart, so one odd quarter does not decide the result. The return figures here are yearly, not quarterly. They show level and direction only; they can support the growth lines but never decide the reading alone. There are fewer than eight usable quarters, so this page does not guess a direction from so little history. ## How much does CRISPR Therapeutics AG earn on its capital? CRISPR Therapeutics AG earned a ROE of −30% in FY25. That is up from a low of −35% in FY22. Its return on capital used (ROIC) is left out: on sales this small it reads −323%, a number that says nothing useful about the business. ## Does CRISPR Therapeutics AG have too much debt? CRISPR Therapeutics AG has total debt of ₹0.8 B against shareholder equity of ₹1.7 B as of Jun 2026, so its debt is 0.45× its equity. Year by year, that ratio went from 0.09 in FY21 to 0.11 in FY25. Keep that borrowing in mind when reading the returns on this page. This company reports in its home currency, not US dollars, so the money charts are left out here. The figures in the text are in that currency (₹); nothing is converted. ## What is the CRISPR Therapeutics AG shareholding pattern? 17.1% of CRISPR Therapeutics AG's tradable shares are in short positions, which are bets that the price will fall, so a large group of traders is betting against it. At normal trading volumes, closing those positions would take about 9.2 days. US companies do not publish a quarter-by-quarter list of owners, so this page uses short interest instead. It is a single reading at one point in time; we do not have its history. Why it is at this level: the figure does not say who holds the short positions or why, so we show the level without guessing the story. ## How far is CRISPR Therapeutics AG from balance-sheet trouble? For CRISPR Therapeutics AG, the Z-score is 2.57. A Z-score above about 3 is safe and below about 1.8 signals danger, so this is in the grey area between the two. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. Why it matters: a Z-score of 2.57 is in the grey area, neither clearly safe nor clearly in trouble. ## How does CRISPR Therapeutics AG rank in its industry? There is no score against its industry: CRISPR Therapeutics AG is not among the largest members shown in this industry comparison for Biotechnology. The score ranks a company within its industry: each measure is scored against the other members. Without that group there is no score, so none is shown. ## Which companies is CRISPR Therapeutics AG compared with? No sector comparison is shown here, not among the largest members shown in this industry comparison. ## Which companies are close to CRISPR Therapeutics AG in size? CRISPR Therapeutics AG is the 45th largest of 211 Biotechnology companies on Sector Alpha by market value (scores of 4 November 2026). Just above it: PTC Therapeutics, Inc., Scholar Rock Holding Corporation and Travere Therapeutics, Inc. Just below it: Dianthus Therapeutics, Inc., Legend Biotech Corporation and Arcutis Biotherapeutics, Inc. ### Biotechnology companies close in size

1. [PTC Therapeutics, Inc.](https://www.sectoralpha.in/us/stocks/ptct) $5.8 billion
2. [Scholar Rock Holding Corporation](https://www.sectoralpha.in/us/stocks/srrk) $5.6 billion
3. [Travere Therapeutics, Inc.](https://www.sectoralpha.in/us/stocks/tvtx) $5 billion
4. CRISPR Therapeutics AG $5 billion
5. [Dianthus Therapeutics, Inc.](https://www.sectoralpha.in/us/stocks/dnth) $4.8 billion
6. [Legend Biotech Corporation](https://www.sectoralpha.in/us/stocks/legn) $4.4 billion
7. [Arcutis Biotherapeutics, Inc.](https://www.sectoralpha.in/us/stocks/arqt) $4.3 billion

[All 211 Biotechnology companies, largest first](https://www.sectoralpha.in/us/sectors/biotechnology#all-companies)

### Companies close in size in other industries

1. [Colliers International Group Inc.](https://www.sectoralpha.in/us/stocks/cigi) $5 billion · Real Estate Services
2. [Applied Digital Corporation](https://www.sectoralpha.in/us/stocks/apld) $5 billion · Information Technology Services
3. CRISPR Therapeutics AG $5 billion
4. [Sprouts Farmers Market, Inc.](https://www.sectoralpha.in/us/stocks/sfm) $5 billion · Grocery Stores
5. [Archrock, Inc.](https://www.sectoralpha.in/us/stocks/aroc) $5 billion · Oil & Gas Equipment & Services

## What else do people ask about CRISPR Therapeutics AG? ### What is CRISPR Therapeutics AG's stock price today? CRISPR Therapeutics AG's stock price is $51.77, −6.1% over the past year. The whole company is worth $5.0 B on the market. In the last 52 weeks it traded between $46 to $60; today it is 42% of the way up from the low, 2.0% below its 200-day average (as of 4 November 2026). ### What were CRISPR Therapeutics AG's latest quarterly results? CRISPR Therapeutics AG reported revenue of ₹0.0 B and a net loss of ₹0.1 B for the Jun 2026 quarter. The operating margin was −1,127.6%, 13,790.7 percentage points higher than a year earlier (as of 4 November 2026). ### What is CRISPR Therapeutics AG's market cap? CRISPR Therapeutics AG's market capitalisation is $5.0 B at a stock price of $51.77. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 4 November 2026). ### How is CRISPR Therapeutics AG performing? CRISPR Therapeutics AG's share price has been falling for 4 weeks. Over the past 13 weeks it has done worse than the S&P 500, for 1 week running. This describes what the data did, not a rating (as of 4 November 2026). ### Will CRISPR Therapeutics AG's stock price go up? This page does not forecast CRISPR Therapeutics AG's stock price. What it shows instead: the stock price is $51.77, and it has been falling for 4 weeks. Nobody can reliably say which way a price will move, and this site does not try (as of 4 November 2026). ### Does CRISPR Therapeutics AG have too much debt? CRISPR Therapeutics AG has a moderate amount of debt: its debt is 0.47× its equity. A year-by-year history of its borrowings is not in our data, so this uses the latest reading. Keep that borrowing in mind when reading the returns on this page (as of 4 November 2026). ### What could break the CRISPR Therapeutics AG story? Biggest thing to watch: the price is not yet in a clear uptrend, so timing is the risk more than the business. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 4 November 2026). ### Is CRISPR Therapeutics AG a stock worth studying right now? What the numbers show: CRISPR Therapeutics AG's share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. The main open question: the next one or two quarters of results. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 4 November 2026). This is research, not advice. We’re not SEBI-registered.